Use of Levosimendan in Cardiac Surgery: An Update After the LEVO-CTS, CHEETAH, and LICORN Trials in the Light of Clinical Practice

Levosimendan is a calcium sensitizer and adenosine triphosphate–dependent potassium channel opener, which exerts sustained hemodynamic, symptomatic, and organ-protective effects. It is registered for the treatment of acute heart failure, and when inotropic support is considered appropriate. In the p...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Cardiovasc Pharmacol
Главные авторы: Guarracino, Fabio, Heringlake, Matthias, Cholley, Bernard, Bettex, Dominique, Bouchez, Stefaan, Lomivorotov, Vladimir V., Rajek, Angela, Kivikko, Matti, Pollesello, Piero
Формат: Artigo
Язык:Inglês
Опубликовано: Journal of Cardiovascular Pharmacology 2018
Предметы:
Drugs in the Pipeline
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5768218/
https://ncbi.nlm.nih.gov/pubmed/29076887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FJC.0000000000000551
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы